In late 2021 a new consensus report, The Management of Type 1 Diabetes in Adults, was published jointly by American Diabetes Association (in Diabetes Care) and European Study for Diabetes (EASD) (in Diabetologia). The report was developed by 14 content experts. The focus, interestingly, is on people 18 years of age and older.
Until recently the only ways to take insulin, other than using an insulin pump, was via traditional pens or vial and syringe. Due to engineering and technological innovation there’s a growing cadre of insulin delivery devices called connected insulin delivery devices. In this blog for T1D Exchange, I define “connected” devices and review the rationale for their need.
For years I’ve heard the terms “FDA-approved,” “FDA-cleared,” and “510-k application,” associated with the review of medical devices at the U.S. FDA, but I wasn’t clear on their definitions.
I was given the golden opportunity to interview a diabetes care and innovation guru, Jeffrey Brewer, for the T1D Exchange.